Refine by
Locations
- Africa
- Algeria
- Angola
- Benin
- Botswana
- Burkina Faso
- Burundi
- Cameroon
- Cape Verde
- Central African Republic
- Chad
- Comoros
- Congo
- Congo, Democratic Republic Of The
- Djibouti
- Egypt
- Equatorial Guinea
- Eritrea
- Ethiopia
- Gabon
- Gambia
- Ghana
- Guinea
- Guinea-Bissau
- Ivory Coast
- Kenya
- Lesotho
- Liberia
- Libya
- Madagascar
- Malawi
- Mali
- Mauritania
- Mauritius
- Morocco
- Mozambique
- Namibia
- Niger
- Nigeria
- Rwanda
- Senegal
- Seychelles
- Sierra Leone
- Somalia
- South Africa
- St. Helena
- Sudan
- Swaziland
- SãO Tomé & PríNcipe
- Tanzania
- Togo
- Tunisia
- Uganda
- Zaire
- Zambia
- Zimbabwe
Candidate Vaccine Equipment & Supplies In Africa
30 equipment items found
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
Icosavax has initiated development of IVX-421, a SARS-CoV-2 vaccine candidate that incorporates an RBD antigen with critical mutations found in the SARS-CoV-2 beta ...
Manufactured by:Virometix AG based inSchlieren, SWITZERLAND
Streptococcus pneumoniae infections cause diseases with considerable morbidity and mortality. Polysaccharide or conjugated vaccines induce serotype-specific antibodies, limiting clinical effectiveness. Emergence of new bacterial serotypes necessitate a new vaccination approach. Virometix is developing an epitope-based, serotype-independent, pneumococcal ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
IVX-121 targets respiratory syncytial virus (RSV), a major cause of viral pneumonia for which no vaccine has been FDA approved. IVX-121 incorporates a stabilized prefusion F antigen licensed from NIAID/NIH (DS-Cav1; Science 2019). RSV F is known to undergo major structural changes that allow viral entry into the host cell, and during that process, critical protective epitopes are lost. Protein ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
Historically, we developed a vaccine candidate against MERS, a novel coronavirus first identified in 2012, as well as a vaccine candidate against SARS in 2005. In 2012, within weeks of obtaining the sequence of the circulating MERS strain, we successfully produced a vaccine candidate. Our MERS ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
Historically, we developed a vaccine candidate against MERS, a novel coronavirus first identified in 2012, as well as a vaccine candidate against SARS in 2005. In 2012, within weeks of obtaining the sequence of the circulating MERS strain, we successfully produced a vaccine candidate. Our MERS ...
Manufactured by:Virometix AG based inSchlieren, SWITZERLAND
Virometix is focusing on the development of vaccine candidates with broad protection against a diverse number of coronaviruses. Our epitope-focused SVLP-based vaccine aims to target specific regions of the Receptor Binding Domain (RBD) of the Spike protein. Proof-of-concept studies are currently ongoing using SARS-CoV-2, where five Synthetic ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
We have developed an EBOV glycoprotein vaccine candidate (Ebola GP vaccine) expressed in insect cells, using our core recombinant baculovirus technology. In 5 separate studies, carried out in collaboration with the National Institute of Allergy and Infectious Diseases, active immunization with the Ebola GP vaccine was shown to be ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
Our recombinant nanoparticle vaccine technology combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic particles that target a variety of viral pathogens. Our recombinant vaccine engineering takes a new approach to provide robust and functional immunity, which may be more efficacious than naturally occurring ...
Manufactured by:Meissa Vaccines, Inc. based inRedwood City, CALIFORNIA (USA)
Meissa is developing MV-012-968, an intranasal (needle-free), adjuvant-free, live attenuated vaccine candidate, to protect infants and at-risk, older adults from RSV. In Phase 1 clinical trials, Meissa’s RSV vaccine candidate was well-tolerated, heavily attenuated, and stimulated a strong RSV-specific mucosal IgA response ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines is developing a GeneVax prime/VesiculoVax boost therapeutic HPV vaccine for use as an adjunct to surgery that targets the seven HPV types responsible for more than 92% of cervical and head and neck ...
Manufactured by:Virometix AG based inSchlieren, SWITZERLAND
In vulnerable patients (infants and elderly) it can cause significant morbidity and mortality. Currently there is no vaccine available in the market and the only prophylaxis is a monoclonal Ab (palivizumab) restricted to high-risk pediatric patients. With V-306 Virometix offers a differentiated approach to RSV vaccine development. Our vaccine ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines has developed a VesiculoVax™-vectored vaccine to protect against Lassa hemorrhagic ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines has also developed a GeneVax prime/VesiculoVax boost therapeutic vaccine that targets all eight HBV genotypes for use as an adjunct to drug ...
Manufactured by:SpyBiotech Limited based inOxford, UNITED KINGDOM
CMV is the most common virus that most people have never heard of, even though it has now been identified as a high priority for vaccines development by key authorities such as the FDA and Institute of ...
Manufactured by:FluGen, Inc. based inMadison, WISCONSIN (USA)
The M2 Deleted Single Replication Live Virus Vaccine (M2SR) offers a potentially differentiating clinical value proposition. FluGen’s flu vaccine candidate works differently, stimulating mucosal, humoral, and cellular immunity, and offering unprecedented efficacy against infection and illness across seven years of virus drift, and ...
Manufactured by:Abera Bioscience AB based inUppsala, SWEDEN
Abera’s proprietary vaccine delivery platform – BERA, enables high-level multivalent presentation of recombinant antigens on bacterial Outer Membrane Vesicles (OMVs) for strong stimulation of the immune ...
Manufactured by:BlueWillow Biologics based inAnn Arbor, MICHIGAN (USA)
Herpes simplex virus-2 (HSV-2) is the leading cause of genital herpes, a sexually transmitted disease affecting over 500 million people worldwide. BlueWillow’s intranasal nanoemulsion (NE) vaccine is uniquely suited to offer protection against this painful and distressing affliction, through its ability to elicit both a systemic and mucosal immune ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
In March 2020, we announced positive top-line results from our Phase 3 clinical trial of our nanoparticle seasonal quadrivalent influenza vaccine candidate, including our proprietary Matrix-M™ adjuvant (NanoFlu™). The trial was a randomized, observer-blinded, active-controlled trial in approximately 2,652 healthy older adults (aged 65 years and older) ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
Developed using cutting-edge structure-based design techniques at the Institute for Protein Design at the UW School of Medicine, IVX-411, our lead vaccine candidate for COVID-19, is a self-assembling protein nanoparticle that displays 60 copies of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) in a highly immunogenic ...
Manufactured by:Meissa Vaccines, Inc. based inRedwood City, CALIFORNIA (USA)
The attenuation of a virus to produce a vaccine must balance reducing its virulence while retaining its ability to stimulate an effective immune response, or immunogenicity. Natural RSV infection does not stimulate a robust immune response, and immunity following SARS-CoV-2 infection wanes, so vaccine technologies that enhance immunogenicity are required. ...